{"entity":{"id":"nct04626518","kind":"trial","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Belzutifan, Lenvatinib and Favezelimab in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) is a phase 1/2 interventional study registered as NCT04626518 by Merck Sharp & Dohme LLC, with 370 participants enrolled, started 2020-12-17 and due to reach its primary completion in 2026-08-21. Interventions recorded: Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab and Favezelimab/Pembrolizumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04626518","url":"https://clinicaltrials.gov/study/NCT04626518"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","belzutifan","lenvatinib","favezelimab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04626518","phase":"1/2","setting":"A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B in Second-Line Metastatic Participants","sponsor":"Merck Sharp & Dohme LLC","enrolled":370,"outcomes":[]},"route":"/trials/nct04626518/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/"},{"id":"favezelimab","kind":"drug","name":"Favezelimab","route":"/drugs/favezelimab/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}